Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 20, 2020 | May 22, 2020 |
| Nabriva Therapeutics plcNBRV · Entity 111497 | Director | January 29, 2023 | February 01, 2023 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 21, 2022 | June 23, 2022 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,007 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 4,047 · Balance 11,007 F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $22.05 · Expires 2030-05-20 | Direct | 8,095 |
Reported balance
After 2020-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-20 · Grant · Acquired 8,095 · Balance 8,095 F2: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.
F2: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer.
Nabriva Therapeutics plc
Report date January 29, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 11,989 |
Reported balance
After 2023-01-29 transaction · row 1
1 source rowRow 1 · 2023-01-29 · Tax withholding · Disposed 431 · Balance 11,989 F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.
OTONOMY, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-06-20 | Direct | 27,500 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 27,500 · Balance 27,500 F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date.
Phathom Pharmaceuticals, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,122 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 45,122 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cidara Therapeutics, Inc.
Report date January 07, 2026 · Filed January 08, 2026
Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $204.40 · Expires 2026-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Disposition to issuer · Disposed 450 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $138.00 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Disposition to issuer · Disposed 550 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.00 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Disposition to issuer · Disposed 550 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.00 · Expires 2029-06-16 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-07 · Disposition to issuer · Disposed 550 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.40 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-07 · Disposition to issuer · Disposed 875 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2031-06-22 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-07 · Disposition to issuer · Disposed 875 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2032-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-07 · Disposition to issuer · Disposed 1,400 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2034-07-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.81 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-07 · Disposition to issuer · Disposed 20,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.31 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-07 · Disposition to issuer · Disposed 11,100 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger").
F3: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2022 Filed Feb 1, 2022 23:37 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantRestricted Stock Units · Derivative | 119,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010487 · tm221371-5_4seq1.xml · derivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,900 Underlying: Ordinary Shares · 119,900 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F3 · date: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F4 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F4 · derivative.expiration_date: Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F3 · derivative.underlying_shares: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F3 · balance_after: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 23:37 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantShare Options · Derivative | 239,800 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-22-010487 · tm221371-5_4seq1.xml · derivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,800 Underlying: Ordinary Shares · 239,800 shares Expires 2032-01-27 F1 · date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F2 · derivative.exercise_date: Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period. F1 · derivative.underlying_shares: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F1 · balance_after: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:19 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 270 | $0.58 | $156.60 |
DisclosureSEC source: 0001104659-22-002736 · tm221371-3_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,502 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:06 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $0.60 | $64.20 |
DisclosureSEC source: 0001104659-22-000973 · tm221371-2_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,772 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 02:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | PurchaseOrdinary Shares | 100,000 | $0.57 | $57,320.00 |
DisclosureSEC source: 0001104659-21-154397 · tm2136401-2_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,879 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5685 to $0.5750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:14 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $0.72 | $162.00 |
DisclosureSEC source: 0001104659-21-147690 · tm2134408-4_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,879 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 23:31 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $0.78 | $83.46 |
DisclosureSEC source: 0001104659-21-145998 · tm2134408-2_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,104 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| November 06, 2021 Filed Nov 9, 2021 22:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.33 | $299.25 |
DisclosureSEC source: 0001104659-21-136404 · tm2132347-2_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,211 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| October 31, 2021 Filed Nov 1, 2021 23:51 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.15 | $123.05 |
DisclosureSEC source: 0001104659-21-132492 · tm2129004d11_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,436 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:39 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.08 | $243.00 |
DisclosureSEC source: 0001104659-21-124665 · tm2129004-8_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,543 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:14 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.19 | $127.33 |
DisclosureSEC source: 0001104659-21-122510 · tm2129004-5_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,768 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 00:00 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | PurchaseOrdinary Shares | 50,000 | $1.13 | $56,500.00 |
DisclosureSEC source: 0001104659-21-116048 · tm2123911-18_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,875 Read SEC document |
| September 06, 2021 Filed Sep 8, 2021 21:27 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.11 | $249.75 |
DisclosureSEC source: 0001104659-21-113876 · tm2123911d16_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,875 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.06 | $113.42 |
DisclosureSEC source: 0001104659-21-112479 · tm2123911-13_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,100 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:16 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.17 | $263.25 |
DisclosureSEC source: 0001104659-21-102956 · tm2123911-11_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,207 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| July 31, 2021 Filed Aug 3, 2021 20:09 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.10 | $117.70 |
DisclosureSEC source: 0001104659-21-099448 · tm2123911-3_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,432 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:11 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.27 | $285.75 |
DisclosureSEC source: 0001104659-21-090218 · tm2121385-6_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,539 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:06 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.35 | $144.45 |
DisclosureSEC source: 0001104659-21-088851 · tm2121385-3_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,764 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 22:01 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001610618-21-000055 · wf-form4_162457203900984.xml · derivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-22 F1 · shares: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders. F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 17:04 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-21-043076 · doc4.xml · derivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-21 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document |
| June 06, 2021 Filed Jun 8, 2021 20:10 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.34 | $301.50 |
DisclosureSEC source: 0001104659-21-078230 · tm2118134d10_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,871 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 20:12 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.38 | $147.66 |
DisclosureSEC source: 0001104659-21-075737 · tm2118134-3_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,096 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| May 06, 2021 Filed May 10, 2021 21:53 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.49 | $335.25 |
DisclosureSEC source: 0001104659-21-064055 · tm2115115-6_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,203 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| April 30, 2021 Filed May 4, 2021 20:03 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.78 | $190.46 |
DisclosureSEC source: 0001104659-21-060949 · tm2115115-1_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,428 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 01:48 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.73 | $389.25 |
DisclosureSEC source: 0001104659-21-048255 · tm2112537-3_4seq1.xml · nonDerivative · entry 3 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,535 F3 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 04/06/2021. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:11 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 107 | $1.66 | $177.62 |
DisclosureSEC source: 0001104659-21-046193 · tm2112032-2_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,680 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| March 06, 2021 Filed Apr 9, 2021 01:48 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 225 | $1.79 | $402.75 |
DisclosureSEC source: 0001104659-21-048255 · tm2112537-3_4seq1.xml · nonDerivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,760 F2 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 03/06/2021. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 00:42 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 106 | $2.39 | $253.34 |
DisclosureSEC source: 0001104659-21-030949 · tm218516-4_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,787 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| February 06, 2021 Filed Apr 9, 2021 01:48 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 2,695 | $2.90 | $7,815.50 |
DisclosureSEC source: 0001104659-21-048255 · tm2112537-3_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,985 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 02/06/2021. Read SEC document |
| January 31, 2021 Filed Feb 3, 2021 01:01 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 125 | $2.62 | $327.50 |
DisclosureSEC source: 0001104659-21-011105 · tm215099-4_4seq1.xml · nonDerivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,893 Read SEC document |
| January 29, 2021 Filed Feb 3, 2021 01:01 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantOrdinary Shares | 117,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-011105 · tm215099-4_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,018 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:15 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 121 | $2.42 | $292.82 |
DisclosureSEC source: 0001104659-21-001032 · tm211621-4_4seq1.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,518 F1 · balance_after: The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 01:21 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.43 | $517.10 |
DisclosureSEC source: 0001104659-20-131222 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,396 Read SEC document |
| October 31, 2020 Filed Nov 3, 2020 00:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.50 | $600.05 |
DisclosureSEC source: 0001104659-20-120641 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,607 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.53 | $645.46 |
DisclosureSEC source: 0001104659-20-111079 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,818 Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:15 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.62 | $750.09 |
DisclosureSEC source: 0001104659-20-101905 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,029 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:08 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.76 | $920.36 |
DisclosureSEC source: 0001104659-20-090281 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,240 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:06 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.67 | $816.94 |
DisclosureSEC source: 0001104659-20-080540 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,451 Read SEC document |
| June 25, 2020 Filed Jun 25, 2020 23:04 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001140361-20-014785 · form4.xml · derivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-06-24 F1 · shares: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders. F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:08 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001209191-20-038946 · doc4.xml · derivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-06-22 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document |
| May 31, 2020 Filed Jun 3, 2020 10:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $1.14 | $1,380.54 |
DisclosureSEC source: 0001104659-20-069182 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,662 F1 · balance_after: The total reported in Column 5 includes 6,187 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan ("ESPP") on May 29, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 8,095 | $0.00 Strike: $22.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000363 · edgar.xml · derivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 Underlying: Common Stock · 8,095 shares Expires 2030-05-20 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000363 · edgar.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,007 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| April 30, 2020 Filed May 4, 2020 22:31 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.55 | $663.99 |
DisclosureSEC source: 0001104659-20-056350 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,686 Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:48 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $0.58 | $696.33 |
DisclosureSEC source: 0001104659-20-042579 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,897 Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 02:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 1,211 | $1.35 | $1,634.85 |
DisclosureSEC source: 0001104659-20-028852 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,108 F1 · balance_after: The total reported in Column 5 includes 5,759 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan ("ESPP") on October 31, 2019. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 01:27 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Options · Derivative | 687,500 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001104659-20-015172 · a4.xml · derivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,500 Underlying: Ordinary Shares · 687,500 shares Expires 2030-02-05 F2 · date: The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F3 · derivative.exercise_date: The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 01:27 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantOrdinary Shares | 343,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-015172 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,560 F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 343,800 restricted stock units. The total reported in Column 5 includes the 343,800 newly awarded restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 01:55 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 16,276 | $1.35 | $21,972.60 |
DisclosureSEC source: 0001104659-20-010897 · a4.xml · nonDerivative · entry 2 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,760 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 20:01 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | PurchaseOrdinary Shares | 50,000 | $1.79 | $89,500.00 |
DisclosureSEC source: 0001104659-19-047723 · a4.xml · nonDerivative · entry 1 Schroeder Theodore R · CIK 0001378690 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Schroeder Living Trust Disclosed balance after: 117,489 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.